Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells

Abstract

PTEN is a tumor suppressor gene that is frequently mutated in human tumors. It functions primarily as a lipid phosphatase and plays a key role in the regulation of phosphatidylinositol-3′-kinase. PTEN appears to play a crucial role in modulating apoptosis by reducing the levels of PtdIns(3,4,5)P3, a phospholipid that activates AKT, a central regulator of apoptosis. To understand the role of PTEN in regulating cell proliferation and apoptosis, we stably overexpressed PTEN in PC3 cells, which are prostate cancer cells that lack PTEN. Overexpression of PTEN in two different clones inhibited cell proliferation and increased serum starvation-induced apoptosis, as compared to control cells. Interestingly, PTEN overexpression resulted in a 44–60% reduction in total insulin-like growth factor-I receptor (IGF-IR) protein levels and a 49–64% reduction in cell surface IGF-IR expression. [35S]methionine pulse experiments in PC3 cells overexpressing PTEN demonstrated that these cells synthesize significantly lower levels of the IGF-IR precursor, whereas PTEN overexpression had no effect on IGF-IR degradation. Taken together, our results show that PTEN can regulate cell proliferation and apoptosis through inhibition of IGF-IR synthesis. These results have important implications for understanding the roles of PTEN and the IGF-IR in prostate cancer cell tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Beresford SA, Davies MA, Gallick GE and Donato NJ . (2001). J. Interferon. Cytokine. Res., 21, 313–322.

  • Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC . (1998). Science, 282, 1318–1321.

  • Chakraborty M, Qiu SG, Vasudevan KM and Rangnekar VM . (2001). Cancer Res., 61, 7255–7263.

  • Comer FI and Parent CA . (2002). Cell, 109, 541–544.

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME . (1997). Cell, 91, 231–241.

  • Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD and Gallick GE . (2002). Clin. Cancer Res., 8, 1904–1914.

  • Dong JT, Li CL, Sipe TW and Frierson Jr HF . (2001). Clin. Cancer Res., 7, 304–308.

  • Dupont J, Khan J, Qu BH, Metzler P, Helman L and LeRoith D . (2001). Endocrinology, 142, 4969–4975.

  • Dupont J, Renou JP, Shani M, Hennighausen L and LeRoith D . (2002). J. Clin. Invest., 110, 815–825.

  • Fernandez M and Eng C . (2002). Clin. Cancer Res., 8, 1695–1698.

  • Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X and Wu H . (2003). Cancer Cell, 3, 117–130.

  • Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA and Yung WK . (2003). Ann. Neurol., 53, 109–117.

  • Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP and Dikic I . (2003). Nat. Cell Biol., 5, 461–466.

  • Huang J and Kontos CD . (2002). Arterioscler. Thromb. Vasc. Biol., 22, 745–751.

  • Jullien J, Guili V, Reichardt LF and Rudkin BB . (2002). J. Biol. Chem., 277, 38700–38708.

  • Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N . (2002). Mol. Cell. Biol., 22, 7831–7841.

  • Koul D, Shen R, Garyali A, Ke LD, Liu TJ and Yung WK . (2002). Int. J. Oncol., 21, 469–475.

  • LeRoith D, Werner H, Beitner-Johnson D and Roberts Jr CT . (1995). Endocr. Rev., 16, 143–163.

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R . (1997). Science, 275, 1943–1947.

  • Ma Q, Renzelli AJ, Baldwin KT and Antonini JM . (2000). J. Biol. Chem., 275, 12676–12683.

  • Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H and Sun H . (2001). Curr. Biol., 11, 263–267.

  • Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C and Bouscary D . (2002). Oncogene, 21, 6587–6597.

  • Reiss K, Porcu P, Sell C, Pietrzkowski Z and Baserga R . (1992). Oncogene, 7, 2243–2248.

  • Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X and Baserga R . (2000). Oncogene, 19, 2687–2694.

  • Seely BL, Samimi G and Webster NJ . (2002). BMC Cancer, 2, 1–9.

  • Sonenberg N and Gingras AC . (1998). Curr. Opin. Cell Biol., 10, 268–275.

  • Stambolic V . (2002). Trends Pharmacol. Sci., 23, 104–106.

  • Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X and Wu H . (2002). Mol. Cell. Biol., 22, 3842–3851.

  • Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH and Testa JR . (2001). Cancer Res., 61, 589–593.

  • Tomic-Carruthers N and Gorden P . (1998). Biochem. Biophys. Res. Commun., 244, 728–731.

  • Vander Heiden MG and Thompson CB . (1999). Nat. Cell Biol., 1, E209–E216.

  • Weng LP, Brown JL and Eng C . (2001a). Hum. Mol. Genet., 10, 237–242.

  • Weng LP, Brown JL and Eng C . (2001b). Hum. Mol. Genet., 10, 599–604.

  • Weng LP, Brown JL, Baker KM, Ostrowski MC and Eng C . (2002). Hum. Mol. Genet., 11, 1687–1696.

  • Weng LP, Smith WM, Brown JL and Eng C . (2001c). Hum. Mol. Genet., 10, 605–616.

  • Wu Y, Yakar S, Zhao L, Hennighausen L and LeRoith D . (2002). Cancer Res., 62, 1030–1035.

  • Yamada KM and Araki M . (2001). J. Cell. Sci., 114, 2375–2382.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Derek LeRoith.

Additional information

This article is a ‘United State Government Work’ paper as defined by the US Copyright Act

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, H., Dupont, J., Yakar, S. et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23, 786–794 (2004). https://doi.org/10.1038/sj.onc.1207162

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207162

Keywords

This article is cited by

Search

Quick links